CA2541869C - Compositions et procedes servant au ciblage de la destruction vasculaire - Google Patents
Compositions et procedes servant au ciblage de la destruction vasculaire Download PDFInfo
- Publication number
- CA2541869C CA2541869C CA2541869A CA2541869A CA2541869C CA 2541869 C CA2541869 C CA 2541869C CA 2541869 A CA2541869 A CA 2541869A CA 2541869 A CA2541869 A CA 2541869A CA 2541869 C CA2541869 C CA 2541869C
- Authority
- CA
- Canada
- Prior art keywords
- cytotoxic
- prodrug
- cells
- phosphate
- vascular
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000002792 vascular Effects 0.000 title claims abstract description 37
- 239000000203 mixture Substances 0.000 title claims abstract description 17
- 230000008685 targeting Effects 0.000 title description 24
- 238000000034 method Methods 0.000 title description 20
- 230000006378 damage Effects 0.000 title description 19
- 150000001875 compounds Chemical class 0.000 claims abstract description 29
- 230000002062 proliferating effect Effects 0.000 claims abstract description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 12
- 241001465754 Metazoa Species 0.000 claims abstract description 11
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims abstract description 10
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229960003966 nicotinamide Drugs 0.000 claims abstract description 5
- 235000005152 nicotinamide Nutrition 0.000 claims abstract description 5
- 239000011570 nicotinamide Substances 0.000 claims abstract description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 20
- 230000003211 malignant effect Effects 0.000 claims description 5
- 125000002091 cationic group Chemical group 0.000 claims description 4
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 229910052749 magnesium Inorganic materials 0.000 claims description 2
- 229910052748 manganese Inorganic materials 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 229910052725 zinc Inorganic materials 0.000 claims description 2
- LQVXSNNAFNGRAH-QHCPKHFHSA-N BMS-754807 Chemical group C([C@@]1(C)C(=O)NC=2C=NC(F)=CC=2)CCN1C(=NN1C=CC=C11)N=C1NC(=NN1)C=C1C1CC1 LQVXSNNAFNGRAH-QHCPKHFHSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- -1 nicotinamide cation Chemical class 0.000 abstract description 6
- 201000010099 disease Diseases 0.000 abstract 2
- 230000002401 inhibitory effect Effects 0.000 abstract 2
- 230000001613 neoplastic effect Effects 0.000 abstract 2
- 229940002612 prodrug Drugs 0.000 description 76
- 239000000651 prodrug Substances 0.000 description 76
- 210000004027 cell Anatomy 0.000 description 50
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 40
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 40
- 102000004243 Tubulin Human genes 0.000 description 40
- 108090000704 Tubulin Proteins 0.000 description 40
- 210000004924 lung microvascular endothelial cell Anatomy 0.000 description 35
- 231100000433 cytotoxic Toxicity 0.000 description 33
- 230000001472 cytotoxic effect Effects 0.000 description 33
- 230000001988 toxicity Effects 0.000 description 33
- 231100000419 toxicity Toxicity 0.000 description 33
- 229910019142 PO4 Inorganic materials 0.000 description 29
- 230000003013 cytotoxicity Effects 0.000 description 27
- 231100000135 cytotoxicity Toxicity 0.000 description 27
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 27
- 239000010452 phosphate Substances 0.000 description 27
- 210000004088 microvessel Anatomy 0.000 description 24
- 239000011230 binding agent Substances 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 239000003814 drug Substances 0.000 description 17
- VXNQMUVMEIGUJW-XNOMRPDFSA-L disodium;[2-methoxy-5-[(z)-2-(3,4,5-trimethoxyphenyl)ethenyl]phenyl] phosphate Chemical compound [Na+].[Na+].C1=C(OP([O-])([O-])=O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 VXNQMUVMEIGUJW-XNOMRPDFSA-L 0.000 description 16
- 230000003021 clonogenic effect Effects 0.000 description 14
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 12
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 12
- 239000002254 cytotoxic agent Substances 0.000 description 12
- 229940127089 cytotoxic agent Drugs 0.000 description 12
- 230000000694 effects Effects 0.000 description 12
- 231100000065 noncytotoxic Toxicity 0.000 description 11
- 230000002020 noncytotoxic effect Effects 0.000 description 11
- LGZKGOGODCLQHG-CYBMUJFWSA-N 5-[(2r)-2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]-2-methoxyphenol Chemical compound C1=C(O)C(OC)=CC=C1C[C@@H](O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-CYBMUJFWSA-N 0.000 description 10
- LGZKGOGODCLQHG-UHFFFAOYSA-N combretastatin Natural products C1=C(O)C(OC)=CC=C1CC(O)C1=CC(OC)=C(OC)C(OC)=C1 LGZKGOGODCLQHG-UHFFFAOYSA-N 0.000 description 10
- 150000004814 combretastatins Chemical class 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 9
- HVXBOLULGPECHP-WAYWQWQTSA-N Combretastatin A4 Chemical compound C1=C(O)C(OC)=CC=C1\C=C/C1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-WAYWQWQTSA-N 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 108090000790 Enzymes Proteins 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 229960005537 combretastatin A-4 Drugs 0.000 description 8
- HVXBOLULGPECHP-UHFFFAOYSA-N combretastatin A4 Natural products C1=C(O)C(OC)=CC=C1C=CC1=CC(OC)=C(OC)C(OC)=C1 HVXBOLULGPECHP-UHFFFAOYSA-N 0.000 description 8
- 231100000599 cytotoxic agent Toxicity 0.000 description 8
- 239000000758 substrate Substances 0.000 description 8
- 210000003556 vascular endothelial cell Anatomy 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
- 231100000002 MTT assay Toxicity 0.000 description 6
- 238000000134 MTT assay Methods 0.000 description 6
- 229930012538 Paclitaxel Natural products 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 230000003511 endothelial effect Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 229960001592 paclitaxel Drugs 0.000 description 6
- 230000035755 proliferation Effects 0.000 description 6
- VREZDOWOLGNDPW-ALTGWBOUSA-N Pancratistatin Chemical compound C1=C2[C@H]3[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)[C@@H]3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-ALTGWBOUSA-N 0.000 description 5
- VREZDOWOLGNDPW-MYVCAWNPSA-N Pancratistatin Natural products O=C1N[C@H]2[C@H](O)[C@H](O)[C@H](O)[C@H](O)[C@@H]2c2c1c(O)c1OCOc1c2 VREZDOWOLGNDPW-MYVCAWNPSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- VREZDOWOLGNDPW-UHFFFAOYSA-N pancratistatine Natural products C1=C2C3C(O)C(O)C(O)C(O)C3NC(=O)C2=C(O)C2=C1OCO2 VREZDOWOLGNDPW-UHFFFAOYSA-N 0.000 description 5
- 239000011734 sodium Substances 0.000 description 5
- 229930192474 thiophene Natural products 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 231100000513 vascular toxicity Toxicity 0.000 description 5
- 210000005166 vasculature Anatomy 0.000 description 5
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 4
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 4
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000010013 cytotoxic mechanism Effects 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000012737 fresh medium Substances 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 230000002503 metabolic effect Effects 0.000 description 4
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 3
- 229940122803 Vinca alkaloid Drugs 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 230000007541 cellular toxicity Effects 0.000 description 3
- 150000001907 coumarones Chemical class 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 229930194832 curacin Natural products 0.000 description 3
- 229930188854 dolastatin Natural products 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 229930013356 epothilone Natural products 0.000 description 3
- HESCAJZNRMSMJG-KKQRBIROSA-N epothilone A Chemical class C/C([C@@H]1C[C@@H]2O[C@@H]2CCC[C@@H]([C@@H]([C@@H](C)C(=O)C(C)(C)[C@@H](O)CC(=O)O1)O)C)=C\C1=CSC(C)=N1 HESCAJZNRMSMJG-KKQRBIROSA-N 0.000 description 3
- 125000004387 flavanoid group Chemical group 0.000 description 3
- 150000002475 indoles Chemical class 0.000 description 3
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000001629 stilbenes Chemical class 0.000 description 3
- 235000021286 stilbenes Nutrition 0.000 description 3
- 150000003577 thiophenes Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 229960003048 vinblastine Drugs 0.000 description 3
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- KEIFWROAQVVDBN-UHFFFAOYSA-N 1,2-dihydronaphthalene Chemical compound C1=CC=C2C=CCCC2=C1 KEIFWROAQVVDBN-UHFFFAOYSA-N 0.000 description 2
- ITZMJCSORYKOSI-AJNGGQMLSA-N APGPR Enterostatin Chemical group C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N1[C@H](C(=O)N[C@@H](CCCN=C(N)N)C(O)=O)CCC1 ITZMJCSORYKOSI-AJNGGQMLSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 208000004434 Calcinosis Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002927 anti-mitotic effect Effects 0.000 description 2
- 229960000074 biopharmaceutical Drugs 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000009510 drug design Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 150000002537 isoquinolines Chemical class 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000003836 peripheral circulation Effects 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- PTMHPRAIXMAOOB-UHFFFAOYSA-N phosphoramidic acid Chemical compound NP(O)(O)=O PTMHPRAIXMAOOB-UHFFFAOYSA-N 0.000 description 2
- 229960005141 piperazine Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000001488 sodium phosphate Substances 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- CQOQDQWUFQDJMK-SSTWWWIQSA-N 2-methoxy-17beta-estradiol Chemical compound C([C@@H]12)C[C@]3(C)[C@@H](O)CC[C@H]3[C@@H]1CCC1=C2C=C(OC)C(O)=C1 CQOQDQWUFQDJMK-SSTWWWIQSA-N 0.000 description 1
- YTVCXBVFGQEBAL-ARJAWSKDSA-N 2-methoxy-5-[(z)-2-(7-methoxy-1,3-benzodioxol-5-yl)ethenyl]phenol Chemical compound C=1C=2OCOC=2C(OC)=CC=1\C=C/C1=CC=C(OC)C(O)=C1 YTVCXBVFGQEBAL-ARJAWSKDSA-N 0.000 description 1
- 102000004008 5'-Nucleotidase Human genes 0.000 description 1
- MIMAKGCYHROECJ-UHFFFAOYSA-N 5,6-dihydroindolo[2,1-a]isoquinoline Chemical class C1=CC=C2CCN3C4=CC=CC=C4C=C3C2=C1 MIMAKGCYHROECJ-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 102000007347 Apyrase Human genes 0.000 description 1
- 108010007730 Apyrase Proteins 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical group OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 1
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 1
- 102000013537 Thymidine Phosphorylase Human genes 0.000 description 1
- 108700023160 Thymidine phosphorylases Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003527 anti-angiogenesis Effects 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000003560 cancer drug Substances 0.000 description 1
- 239000012830 cancer therapeutic Substances 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 231100000096 clonogenic assay Toxicity 0.000 description 1
- 238000009643 clonogenic assay Methods 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- HRRAOGKGGZFKSW-UHFFFAOYSA-N combretastatin A2 Natural products COc1ccc(C=C/c2cc(O)c3OCOc3c2)cc1OC HRRAOGKGGZFKSW-UHFFFAOYSA-N 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000824 cytostatic agent Substances 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000007402 cytotoxic response Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylenetetramine Chemical compound C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 210000004925 microvascular endothelial cell Anatomy 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 231100001083 no cytotoxicity Toxicity 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- NQQWFVUVBGSGQN-UHFFFAOYSA-N phosphoric acid;piperazine Chemical compound OP(O)(O)=O.C1CNCCN1 NQQWFVUVBGSGQN-UHFFFAOYSA-N 0.000 description 1
- 229960001954 piperazine phosphate Drugs 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 108010043671 prostatic acid phosphatase Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000008280 toxic mechanism Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 239000003744 tubulin modulator Substances 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12047899P | 1999-02-18 | 1999-02-18 | |
| US60/120,478 | 1999-02-18 | ||
| CA2358925A CA2358925C (fr) | 1999-02-18 | 2000-02-16 | Compositions et procedes servant au ciblage de la destruction vasculaire |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2358925A Division CA2358925C (fr) | 1999-02-18 | 2000-02-16 | Compositions et procedes servant au ciblage de la destruction vasculaire |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2541869A1 CA2541869A1 (fr) | 2000-08-24 |
| CA2541869C true CA2541869C (fr) | 2013-06-11 |
Family
ID=32094420
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2541869A Expired - Lifetime CA2541869C (fr) | 1999-02-18 | 2000-02-16 | Compositions et procedes servant au ciblage de la destruction vasculaire |
| CA002455956A Abandoned CA2455956A1 (fr) | 1999-02-18 | 2000-02-16 | Compositions et procedes servant au ciblage de la destruction vasculaire |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002455956A Abandoned CA2455956A1 (fr) | 1999-02-18 | 2000-02-16 | Compositions et procedes servant au ciblage de la destruction vasculaire |
Country Status (1)
| Country | Link |
|---|---|
| CA (2) | CA2541869C (fr) |
-
2000
- 2000-02-16 CA CA2541869A patent/CA2541869C/fr not_active Expired - Lifetime
- 2000-02-16 CA CA002455956A patent/CA2455956A1/fr not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CA2455956A1 (fr) | 2000-08-24 |
| CA2541869A1 (fr) | 2000-08-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2358925C (fr) | Compositions et procedes servant au ciblage de la destruction vasculaire | |
| JP2002537262A5 (fr) | ||
| Freeman et al. | The source of choline for acetylcholine synthesis in brain | |
| Szewczyk et al. | Mitochondria as a pharmacological target | |
| Giraud et al. | Oxazaphosphorines: new therapeutic strategies for an old class of drugs | |
| Levade et al. | Signalling sphingomyelinases: which, where, how and why? | |
| Cai | Small molecule vascular disrupting agents: potential new drugs for cancer treatment | |
| Bernardi et al. | Mitochondrial energy dissipation by fatty acids: Mechanisms and implications for cell death | |
| KR101113436B1 (ko) | 약학적 제제의 제조를 위한 화학식 ａ?ｒ?ｘ의 화합물 | |
| Ghasemi et al. | Integrated sphingosine-1 phosphate signaling in the central nervous system: from physiological equilibrium to pathological damage | |
| Konieczny et al. | Lack of neuroprotective effect of celastrol under conditions of proteasome inhibition by lactacystin in in vitro and in vivo studies: implications for Parkinson’s disease | |
| Lim et al. | MK886-induced apoptosis depends on the 5-LO expression level in human malignant glioma cells | |
| MXPA01008245A (es) | Combinaciones para el tratamiento de las enfermedades que comprenden angiogenesis. | |
| Öz et al. | Effects of different doses of curcumin on apoptosis, mitochondrial oxidative stress and calcium ion influx in DBRG glioblastoma cells | |
| Bédouet et al. | In vitro evaluation of (S)-ibuprofen toxicity on joint cells and explants of cartilage and synovial membrane | |
| US20060100179A1 (en) | Compositions and methods for use in targeting vascular destruction | |
| Gu et al. | Inhibiting myosin light chain kinase retards the growth of mammary and prostate cancer cells | |
| CA2541869C (fr) | Compositions et procedes servant au ciblage de la destruction vasculaire | |
| EP1810680A2 (fr) | Compositions et procédé d'utilisation pour le ciblage de la destruction vasculaire | |
| AU2004201471B2 (en) | Compositions and Methods for Use in Targeting Vascular Destruction | |
| Sanchez et al. | The effect of high molecular phospholipase A2 inhibitors on 3T6 fibroblast proliferation | |
| Wang et al. | Cdc25A protein phosphatase: a therapeutic target for liver cancer therapies | |
| MXPA01008291A (en) | Compositions and methods for use in targeting vascular destruction | |
| US20100028417A1 (en) | Use of substituted glycerin derivatives for producing a pharmaceutical preparation | |
| Roy et al. | Recent advances of application of Berberin on phospholipase A2 (PLA2): A novel and potent therapeutic inhibitor in targeting lung cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKEX | Expiry |
Effective date: 20200217 |